Generics/General
Safety and compliance fears delay UK’s generics substitution
Plans to allow pharmacists to save the UK’s National Health Service (NHS) money by overruling doctors' prescriptions for branded medicines have been delayed after concerns about patient safety and compliance.
Growing western generic APIs markets in India and China
The developing countries India and China represent growing markets for active pharmaceutical ingredients (APIs) from western regulated markets. This is the conclusion of Ms Kate Kuhrt, Director of Generics and API Intelligence at Thomson Reuters. “With the pharmaceutical markets in India and China expected to continue to grow at double-digit rates, while traditional pharmaceutical markets, such as the US, Japan and Western Europe remain stagnant, it is no surprise that many API manufacturers have set their eyes on India and China”, she states.
Pressures on generic medicines put EU healthcare at risk
“The future of the European generic medicines industry is under serious threat, which places both the sustainability of European health care and the European industrial competitiveness at serious risk,” warned Mr Greg Perry, Director General of the European Generics medicines Association (EGA), at an EGA conference on healthcare sustainability on 31 March 2009 in Prague, Czech Republic.
